Research Paper Volume 15, Issue 20 pp 11639—11653

Figure 1. Alisol A improved neurological deficits and cognitive impairment after CI. (A) The molecular formula of alisol A. (B) Neurobehavioral function of mice was evaluated by mNSS at 1, 3, 5, and 7 days after CI, n = 10. (C) Escape latency of each group in the MWM training stage. (D) Total distance traveled by each group in the MWM training stage. (E) Frequency of crossing the target quadrant of each group in the MWM test. (F) Time spent in the target quadrant of each group in the MWM test. (G) Discrimination ratio of each group in NORT. (H) Representative tracking images in the MWM test. (I) Representative tracking images in NORT, n = 10. Data are shown as the mean ± SD. ^**P < 0.01, ^***P < 0.001 compared with the sham group, ^##P < 0.01, ^###P < 0.001 compared with the CI group, ^@@P < 0.01, ^@@@P < 0.001 compared with the CI+AA group. Note: sham-operated group (sham group); cerebral ischemia group (CI group); cerebral ischemia + alisol A (CI+AA group); cerebral ischemia + alisol A+AKT inhibitor group (CI+AA+inh group).